# Deep Intelligent Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/deep-intelligent-pharma

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.dip-ai.com
- Total disclosed funding: $65M
- Latest round: Series D (Dec 11, 2025)
- Investors on record: 5

## About

Founded in 2017 and based in Beijing, China, Beijing Deep Intelligent Pharma Technology Co., Ltd., doing business as Deep Intelligent Pharma, develops artificial intelligence platforms that support clinical research for the pharmaceutical industry. The company first focused on individual artificial intelligence functions before expanding into a clinical research platform that can support planning, study simulation and study execution. It created a large collection of specialized digital agents that complete small research tasks and work together in complex study environments. Its technology has been used in more than 40,000 projects for over 1,000 pharmaceutical companies. The firm continues to expand its delivery network and technical infrastructure. In March 2026, Deep Intelligent Pharma raised USD 40 million in venture funding from CDH Baifu Capital, Xin Ding Capital, Jinyi Capital, Kaitai Capital.

The company works with pharmaceutical companies and research institutions to provide clinical research platforms that include planning tools, study simulation, document analysis and automated task execution. Its system divides clinical research into many small tasks that are completed by specialized digital agents.

The company generates revenue from enterprise contracts for the clinical research platform, from project delivery services for study planning and execution, and from software access.

## Funding rounds

- Series D, Dec 11, 2025, $50M — Xin Ding Capital, HSG, CDH Baifu Capital
- Series B, Dec 1, 2019 — SIG Asia Investment
- Series B, Oct 9, 2018, $15M — HSG
- Series A, Mar 1, 2018 — ZhenFund

## Investors

- ZhenFund (https://capitalatlas.ai/funds/zhenfund) — Series A
- HSG (https://capitalatlas.ai/funds/hsg) — Series B, Series D
- SIG Asia Investment (https://capitalatlas.ai/funds/sig-asia-investment) — Series B
- Xin Ding Capital (https://capitalatlas.ai/funds/xin-ding-capital) — Series D
- CDH Baifu Capital (https://capitalatlas.ai/funds/cdh-baifu-capital) — Series D